However, therapeutic responses have been observed in patients with PD-L1–negative tumors, and the prognostic/predictive utility of tumor PD-L1 expression has yet to be validated because such expression is heterogeneous and may be affected by prior therapies [12]. This evidence concerns the gene CD274 and neoplasm.